Two-visit HDR radiation to treat early prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a radiation treatment delivered in two fractions (two sessions) as the only treatment for certain early-stage prostate cancers. It may help you avoid other treatments, like hormone therapy, depending on whether your cancer and health history fit the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed prostate cancer (adenocarcinoma) based on biopsy or tests
- Your prostate cancer is “low to intermediate risk” (per standard risk categories)
- You have never had prostate cancer treatment and have never had hormone (androgen deprivation) therapy
- You must be able to safely have HDR brachytherapy, likely with general anesthesia, as your radiation doctor decides
- Your daily functioning is limited but you’re still able to do most activities (ECOG less than 2)
- If you have HIV or hepatitis B/C, your virus levels must be controlled as required by the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
This study compares two types of radiation therapy for low- to intermediate-risk prostate cancer. One uses tiny radioactive seeds placed inside the prostate (brachytherapy), the other uses very high doses of external radiation over fewer sessions. The goal is to see which has fewer side effects while still being effective.
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.